Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 May 2023 | Story Leonie Bolleurs | Photo Supplied
Prof André Roodt
Prof Andreas Roodt was recently awarded the MT Steyn Prize for Natural Science and Technology Excellence from the SA Akademie vir Wetenskap en Kuns. He will receive the prize, sponsored by Sanlam, at a function scheduled for September this year.

Prof Andreas Roodt, former Head of the Department of Chemistry at the University of the Free State (UFS) and retired Distinguished Professor in the same department, was recently awarded the MT Steyn Prize for Natural Science and Technology Excellence from the SA Akademie vir Wetenskap en Kuns.

The prize, a major recognition of his life's work, was presented to him for his contribution to the exploration and sustained development of natural science and technology and the successful application thereof in broader society.

Impacting society

About receiving the prize, he says it was a big surprise, but he is very proud to be honoured with this special award, “being an Afrikaans kid from a ‘platteland’ school outside Bloemfontein.”

Prof Roodt’s research focuses on understanding the reaction mechanisms of mainly inorganic coordination chemical systems that are critical to different industrial, medical, environmental, and metal beneficiation processes.

His research, for instance, contributes to important compounds and processes relevant to nuclear medicine and potential cancer therapy. Not so long ago, he registered a patent on this in Europe, Japan, and the USA that could help to diagnose and potentially treat cancer-related tumours in the future.

In addition, he continues to work on several projects aimed at developing cleaner industrial processes in the South African petrochemical industry. He is also focusing on more efficient ways of accessing the country’s mineral resources.

Career highlights

Throughout his academic career, Prof Roodt has achieved many significant milestones. He was extensively involved in crystallography for more than 30 years. One of his career highlights was being elected as the President of the European Crystallographic Association from 2012 to 2015, an organisation with more than 35 member countries.

In this field, he established an X-ray crystallographic facility in the UFS Department of Chemistry, which was officially named the ‘Roodt XRD Lab’ at the end of 2021.

He also sees his journey with the diverse group of 41 PhD and 54 MSc students (Afrikaans, English, Sesotho, Setswana, and isiXhosa) as another notable achievement in his career.

Other outstanding moments in Prof Roodt's career were his collaborations with research leaders from countries such as the USA, UK, Switzerland, Italy, Sweden, France, Croatia, India, Japan, Russia, the Netherlands, Germany, and Tunisia. These collaborations have allowed him to be recognised by peers worldwide and have demonstrated that Africa and South Africa can produce high-quality and relevant research that can compete on an international level.

The future

Despite his appointment as a Distinguished Professor and his commitment to finishing uncompleted work and assisting younger colleagues both in South Africa and abroad, Prof Roodt retired more than a year ago. He is now enjoying his retirement with his wife, children, and grandchildren, while also devoting time to his passion for collecting aloe plants and generating new hybrids.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept